Several of these method-of-use patents were filed after the core molecule patents and are plausible CIP candidates based on filing sequences visible in the Orange Book
My body was telling me, Hey, we need a little time-out, and I listened. One of the most valuable lessons she learned
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
The drug class evolved through iteration, not revolution: GLP-1 Drug Class Evolution twice-daily injections once-weekly dosing entered popular culture Cultural moment dual GLP-1 + GIP agonist More potent + glucagon receptor Coming Each generation solved a limitation of the one before it, a drug class earning clinical confidence incrementally over two decades of real-world use
Garca-Miranda A, Solano-Alcal KA, Montes-Alvarado JB, Rosas-Cruz A, Reyes-Leyva J, Navarro-Tito N, et al